Your browser doesn't support javascript.
Drug-induced liver injury in COVID-19 patients during hospitalization.
Chen, Ying; Shi, Cai; Zhan, Haiyan; Yang, Boning; Liu, Jun; Rong, Peipei; Luo, Yi; Yang, Jian.
  • Chen Y; Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan, China.
  • Shi C; Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan, China.
  • Zhan H; Department of Pharmacy, Wuhan Jinyintan Hospital, Wuhan, China.
  • Yang B; Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
  • Liu J; Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan, China.
  • Rong P; Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan, China.
  • Luo Y; Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan, China.
  • Yang J; Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan, China.
Medicine (Baltimore) ; 102(11): e33294, 2023 Mar 17.
Article in English | MEDLINE | ID: covidwho-2254676
ABSTRACT
Since coronavirus disease 2019 (COVID-19) outbreaks in December 2019 in Wuhan, almost no studies have systematically described drug-induced liver injury (DILI) in COVID-19 patients. This study aimed to assess the characteristics of liver test abnormality or liver injury in patients with COVID-19, and further to explore DILI in COVID-19 patients during hospitalization. It was a single-center retrospective analysis of confirmed severe acute respiratory syndrome coronavirus 2 infected patients in the hospital from January 2020 to March 2020. Univariate and multivariate logistic regression analysis were used to assess the risk factors associated with liver test abnormality or liver injury. At admission, 148 (48.8%, 148/303) patients had abnormal liver test results and 7 (2.4%, 7/303) had liver injury, while 195 (64.4%, 195/303) had abnormal liver test results and 17 (5.6%, 17/303) had liver injury during hospitalization. After excluding these patients with liver disease and liver function abnormalities or liver injury at admission, 15 (11.1%, 15/135) patients developed DILI during hospitalization. Further regression analysis indicated that methylprednisolone (odds ratio = 4.177, 95% confidence interval [1.106-15.771], P = .035), but not Chinese herbal medicine or other used drug, was associated with DILI in patients during hospitalization. Abnormal liver function results were in more than half of patients with COVID-19, and the incidence of DILI in COVID-19 patients was 11.1% during hospitalization. Liver test abnormality or liver injury in patients might be directly caused by the viral infection at admission, but the detrimental effects on liver injury mainly related to certain medications used during hospitalization, particularly methylprednisolone. Severe COVID-19 could increase the occurrence of liver injury (P = .007) during hospitalization, but not a risk factor of liver injury. However, Chinese herbal medicine was a protective factor for liver injury.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Chemical and Drug Induced Liver Injury / COVID-19 Type of study: Etiology study / Observational study / Prognostic study Topics: Long Covid / Traditional medicine Limits: Humans Language: English Journal: Medicine (Baltimore) Year: 2023 Document Type: Article Affiliation country: MD.0000000000033294

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Chemical and Drug Induced Liver Injury / COVID-19 Type of study: Etiology study / Observational study / Prognostic study Topics: Long Covid / Traditional medicine Limits: Humans Language: English Journal: Medicine (Baltimore) Year: 2023 Document Type: Article Affiliation country: MD.0000000000033294